Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesDividends payablesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Vycor Medical (VYCO) Raw Materials (2016 - 2025)

Vycor Medical has reported Raw Materials over the past 10 years, most recently at $56088.0 for Q4 2025.

  • Quarterly Raw Materials rose 16.79% to $56088.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $56088.0 through Dec 2025, up 16.79% year-over-year, with the annual reading at $56088.0 for FY2025, 16.79% up from the prior year.
  • Raw Materials was $56088.0 for Q4 2025 at Vycor Medical, down from $58846.0 in the prior quarter.
  • Over five years, Raw Materials peaked at $109894.0 in Q4 2022 and troughed at $48024.0 in Q4 2024.
  • The 5-year median for Raw Materials is $58578.0 (2025), against an average of $69345.0.
  • Year-over-year, Raw Materials surged 42.41% in 2022 and then crashed 45.57% in 2024.
  • A 5-year view of Raw Materials shows it stood at $77166.0 in 2021, then soared by 42.41% to $109894.0 in 2022, then decreased by 19.71% to $88236.0 in 2023, then crashed by 45.57% to $48024.0 in 2024, then grew by 16.79% to $56088.0 in 2025.
  • Per Business Quant, the three most recent readings for VYCO's Raw Materials are $56088.0 (Q4 2025), $58846.0 (Q3 2025), and $58196.0 (Q2 2025).